antiangiogenic therapy
Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles
... monitor antiangiogenic therapy response by molecular MRI over common anatomical approaches, a time point of day 4 after treatment was chosen to study the early therapeutic response of ...to ...
12
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
... Increased platelet infiltration into tumors after withdrawal of antiangiogenic therapy. We and others have shown that platelets enhance tumor growth (19, 23, 26), chemoresistance (20), and metastasis (21, ...
13
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
... anti-angiogenic therapy [10, ...to therapy than the original tumor ...successful antiangiogenic therapy in solid tumors but ultimately limits its therapeutic potential by enhancing the ...
12
<p>Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy</p>
... Purpose: Antiangiogenic drugs usually have short-acting efficacy and poor treatment ...The antiangiogenic effects of MSN-bevacizumab nanoparticles were evaluated in vitro and in ...
13
Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multidrug-resistant breast cancer
... chemo-combined therapy,[14] suggesting the need of a more effective approach to overcome ...resistance. Antiangiogenic therapy that mainly attempts to perturb the angiogenic potential of tumor ...
18
Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?
... The central importance of angiogenesis and our understanding of how new blood vessels are formed have led to the development of novel antiangiogenic therapies. Although the number of agents in development has ...
5
The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer
... for antiangiogenic therapy for CRC, particularly when traditional anti-VEGF therapies fail or tumors develop resistance to strategies targeting a single angiogenic signaling ...
16
Comparison of Radiological Criteria (RECIST MASS SACT Choi) in Antiangiogenic Therapy of Renal Cell Carcinoma
... targeted antiangiogenic therapy led to a marked improvement in terms of both survival and in terms of Progression Free Survival (PFS) in patients with metastatic ...during therapy with tyrosine ...
5
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
... of antiangiogenic drugs for the treatment of metastatic disease, a large number of issues remains ...to antiangiogenic therapy will be ...on antiangiogenic drugs in metastatic colorectal ...
14
Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects
... monitoring antiangiogenic therapy ...assessing antiangiogenic therapy effects in subcuta- neous A431 ...of therapy response in cancer by apoptosis imaging can be misleading, depend- ing ...
10
GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance
... Specific pharmacologic inhibitors of GLUT3 are not available at present but will be important to devel- op as cancer treatments, including in conjunction with antiangiogenic therapy. For now, based on a ...
19
Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects
... Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC ...
8
<p>Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review</p>
... radio- therapy or chemotherapy for malignant BSG, we made the decision to treat the patient with combined-modality manage- ...combined antiangiogenic therapy may achieve a meaningful ...
7
Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)
... predicting antiangiogenic therapy-associated PH could be clearly identified from the ...of antiangiogenic therapy in patients with NSCLC, particularly in light of the de- velopment of newer ...
6
Original Article Synergistic effects and mechanism of Danshen injection in combination with chemotherapy and antiangiogenic therapy for colon cancer
... anti-VEGF therapy for treatment of metastatic colon carcinoma, a PDX model of colon cancer hepatic metastases was estab- lished, based on which efficacy of Danshen in- jection was evaluated, in terms of single ...
8
Antiangiogenic therapy for breast cancer
... of therapy but the results were not always reported separately ...line therapy revealed encouraging results with an 81% clinical benefit rate (CBR; 6% complete response (CR), 33% partial response (PR) and ...
16
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
... scribed for soft tissue hemangiomas of infancy. Re- gression of the tumor began after 3 weeks of therapy and paralleled decreasing urinary bFGF. However, after 4 months the tumor stopped shrinking and urinary bFGF ...
7
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
... The majority of patients (86.2%) had a nephrectomy, only 14,5% and 13,6% didn’t undergo nephrectomy in GM and NGM group respectively. Of the patients who did not undergo a nephrectomy, 70% had primary metastatic disease ...
24
Successful Antiangiogenic Therapy of Giant Cell Angioblastoma With Interferon Alfa 2b: Report of 2 Cases
... sc daily. After 6 days of therapy, the patient’s SGOT rose to 274 (normal range for infant ⬍ 1 year: 10 – 65) and IFN␣2b was stopped. Over the next few weeks, the SGOT decreased to 73 and the medication was ...
7
Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
... photodynamic therapy (PDT) with verteporfin have also not been ...todynamic Therapy (TAP) or Verteporfin in Photodynamic Therapy (VIP) trials, 16,17 a recent study 18 enrolling lesions ...
6